Newborn bloodspot screening policy framework for Australia.
暂无分享,去创建一个
[1] J. Gray,et al. Evidence based policy making , 2004, BMJ : British Medical Journal.
[2] B. Wilfond,et al. Parental Permission for Pilot Newborn Screening Research: Guidelines From the NBSTRN , 2014, Pediatrics.
[3] S. Warren,et al. Newborn screening for developmental disabilities: reframing presumptive benefit. , 2005, American journal of public health.
[4] J. Bonham. Impact of new screening technologies: should we screen and does phenotype influence this decision? , 2013, Journal of Inherited Metabolic Disease.
[5] B. Kosofsky,et al. Newborn screening for Krabbe disease: the New York State model. , 2009, Pediatric neurology.
[6] D. Fitzgerald,et al. Long-term outcomes of children with intermediate sweat chloride values in infancy. , 2015, The Journal of pediatrics.
[7] Domenica Taruscio,et al. A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document , 2013, European Journal of Human Genetics.
[8] A. Andermann,et al. Guiding Policy Decisions for Genetic Screening: Developing a Systematic and Transparent Approach , 2009, Public Health Genomics.
[9] J. Puck,et al. Hematopoietic stem cell transplantation for severe combined immunodeficiency in the neonatal period leads to superior thymic output and improved survival. , 2002, Blood.
[10] H. Dawkins,et al. New mothers' awareness of newborn screening, and their attitudes to the retention and use of screening samples for research purposes , 2005, Genomics, society, and policy.
[11] John J. Mitchell,et al. Achieving the “triple aim” for inborn errors of metabolism: a review of challenges to outcomes research and presentation of a new practice-based evidence framework , 2012, Genetics in Medicine.
[12] D. Taruscio,et al. Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 2 – From screening laboratory results to treatment, follow-up and quality assurance , 2012, Journal of Inherited Metabolic Disease.
[13] B. Potter,et al. Newborn Screening by Tandem Mass Spectrometry , 2007, Canadian journal of public health = Revue canadienne de sante publique.
[14] R. Guthrie,et al. A SIMPLE PHENYLALANINE METHOD FOR DETECTING PHENYLKETONURIA IN LARGE POPULATIONS OF NEWBORN INFANTS. , 1963, Pediatrics.
[15] P. O'Leary,et al. Economic evaluation of neonatal screening for phenylketonuria and congenital hypothyroidism , 2005, Journal of paediatrics and child health.
[16] D. Studdert,et al. Newborn screening cards: a legal quagmire , 2011, The Medical journal of Australia.
[17] D. Amor,et al. Implementation of written consent for newborn screening in Victoria, Australia , 2014, Journal of paediatrics and child health.
[18] K. Wilson,et al. Developing a National Newborn Screening Strategy for Canada , 2010 .
[19] Gary L Hoffman,et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: A worldwide collaborative project , 2011, Genetics in Medicine.
[20] A. Woodhouse. Evidence and practice. , 2005, Mental health today.
[21] E. Haan,et al. Human Genetics Society of Australasia Position Statement: Population-Based Carrier Screening for Cystic Fibrosis , 2014, Twin Research and Human Genetics.
[22] Jennifer Couzin-Frankel,et al. Science Gold Mine, Ethical Minefield , 2009, Science.
[23] B. Wilcken,et al. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. , 2003, The New England journal of medicine.
[24] D. Atkins,et al. Making policy when the evidence is in dispute. , 2005, Health affairs.
[25] S. Timmermans,et al. Newborn screening and maternal diagnosis: rethinking family benefit. , 2011, Social science & medicine.
[26] David Holmes. Europe plays catch-up on neonatal screening as US skips ahead , 2012, Nature Medicine.
[27] B. Wilcken,et al. Fifty years of newborn screening , 2015, Journal of paediatrics and child health.